US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

SNGX

Soligenix (SNGX)

Soligenix Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SNGX

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
24/05/2024	15:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNGX	Soligenix Inc
24/05/2024	06:30	PR Newswire (US)	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting	NASDAQ:SNGX	Soligenix Inc
23/05/2024	06:30	PR Newswire (US)	Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split	NASDAQ:SNGX	Soligenix Inc
22/05/2024	15:05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:SNGX	Soligenix Inc
21/05/2024	11:35	GlobeNewswire Inc.	PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon	NASDAQ:SNGX	Soligenix Inc
21/05/2024	06:30	PR Newswire (US)	SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference	NASDAQ:SNGX	Soligenix Inc
20/05/2024	06:30	PR Newswire (US)	Soligenix Encourages Stockholders to Vote Prior to Annual Meeting	NASDAQ:SNGX	Soligenix Inc
16/05/2024	06:30	PR Newswire (US)	Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice	NASDAQ:SNGX	Soligenix Inc
10/05/2024	15:16	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:SNGX	Soligenix Inc
10/05/2024	15:05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNGX	Soligenix Inc
10/05/2024	06:30	PR Newswire (US)	Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results	NASDAQ:SNGX	Soligenix Inc
06/05/2024	06:30	PR Newswire (US)	Soligenix to Present at Upcoming Conferences	NASDAQ:SNGX	Soligenix Inc
25/04/2024	06:30	PR Newswire (US)	Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa	NASDAQ:SNGX	Soligenix Inc
18/04/2024	07:30	PR Newswire (US)	Soligenix Announces Pricing of $4.75 Million Public Offering	NASDAQ:SNGX	Soligenix Inc
15/04/2024	06:30	PR Newswire (US)	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection	NASDAQ:SNGX	Soligenix Inc
11/04/2024	06:30	PR Newswire (US)	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection	NASDAQ:SNGX	Soligenix Inc
03/04/2024	06:30	PR Newswire (US)	Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency	NASDAQ:SNGX	Soligenix Inc
15/03/2024	06:30	PR Newswire (US)	Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results	NASDAQ:SNGX	Soligenix Inc
08/02/2024	06:30	PR Newswire (US)	Soligenix Announces Formation of Behçet's Disease Medical Advisory Board	NASDAQ:SNGX	Soligenix Inc
25/01/2024	06:30	PR Newswire (US)	Soligenix to Present at The Microcap Conference	NASDAQ:SNGX	Soligenix Inc
08/01/2024	06:30	PR Newswire (US)	FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	NASDAQ:SNGX	Soligenix Inc
04/01/2024	06:30	PR Newswire (US)	Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis	NASDAQ:SNGX	Soligenix Inc
02/01/2024	06:30	PR Newswire (US)	Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses	NASDAQ:SNGX	Soligenix Inc
17/12/2023	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SNGX	Soligenix Inc
15/12/2023	15:10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SNGX	Soligenix Inc
08/12/2023	15:05	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:SNGX	Soligenix Inc
01/12/2023	06:30	PR Newswire (US)	"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery	NASDAQ:SNGX	Soligenix Inc
30/11/2023	06:30	PR Newswire (US)	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease	NASDAQ:SNGX	Soligenix Inc
13/11/2023	06:30	PR Newswire (US)	Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results	NASDAQ:SNGX	Soligenix Inc
16/10/2023	06:30	PR Newswire (US)	Soligenix to Present at The ThinkEquity Conference	NASDAQ:SNGX	Soligenix Inc

Showing the most relevant articles for your search:NASDAQ:SNGX

1 2 3 4 5 6 7 8 9 10 Próxima >

Hsbc Bank Usa Na Dual Di...

BNP Paribas Issuance

SMC Entertainment (PK)

Tower Resources

Polo Capital Securitizad...

PTK Acquisition

Liberty Latin America

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones